Physician profile
Roman Davidenko
NPI 1366739039
$622.24
in general payments reported to CMS, 2019-2025
19 companies · $47.52 in 2025
The $47.52 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.34 · 2020: $12.12 · 2021: $43.05 · 2022: $137 · 2023: $225 · 2024: $63.61 · 2025: $47.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.62 | 2019-2022 | |
| Inspire Medical Systems, INC. | $101.68 | 2023 | Inspire |
| Astrazeneca Pharmaceuticals LP | $48.15 | 2024-2025 | Airsupra |
| Novo Nordisk INC | $45.21 | 2019-2024 | |
| Astellas Pharma US INC | $36.13 | 2023 | Myrbetriq, Veozah |
| Nevro Corp. | $33.17 | 2022 | |
| Horizon Therapeutics Plc | $30.51 | 2022-2023 | Krystexxa |
| Boston Scientific Corporation | $30.45 | 2023 | Watchman Access System, Rezum Generator |
| Novartis Pharmaceuticals Corporation | $21.05 | 2023 | |
| Mylan Pharmaceuticals INC. | $20.95 | 2019 | |
| Merck Sharp & Dohme LLC | $19.26 | 2023 | Vaxneuvance, Vaxelis, Rotateq |
| Biohaven Pharmaceutical Holding Company LTD. | $17.99 | 2022 | |
| Amgen INC. | $17.03 | 2025 | Krystexxa |
| Qiagen, LLC | $16.73 | 2024 | |
| Sanofi Pasteur INC. | $15.54 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $14.05 | 2021 | |
| Glaxosmithkline, LLC. | $14.02 | 2022 | |
| Lilly USA, LLC | $13.99 | 2025 | Zepbound, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roman Davidenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.